Carlecortemcel-L
Alternative Names: Haematopoetic stem cell therapy - Teva/Gamida-Cell; StemExLatest Information Update: 02 Oct 2021
At a glance
- Originator Teva Pharmaceutical Industries - Gamida-Cell (JV)
- Developer Loyola University Chicago; Teva Pharmaceutical Industries - Gamida-Cell (JV)
- Class Antineoplastics; Haematopoietic stem cells therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Haematological malignancies
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 16 Oct 2015 Discontinued - Phase-II for Haematological malignancies (In the elderly) in USA (IV) before October 2015
- 16 Oct 2015 Discontinued - Phase-II/III for Haematological malignancies (In adolescents, In adults) in Hungary (IV) before October 2015
- 16 Oct 2015 Discontinued - Phase-II/III for Haematological malignancies (In adolescents, In adults) in Israel (IV) before October 2015